

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2007 (25.10.2007)

PCT

(10) International Publication Number
WO 2007/118651 A1

(51) International Patent Classification:
C07D 223/12 (2006.01) **A61P 11/00** (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:
PCT/EP2007/003213

(22) International Filing Date: 11 April 2007 (11.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0607532.9 13 April 2006 (13.04.2006) GB
0610244.6 23 May 2006 (23.05.2006) GB

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PORTMANN, Robert** [CH/CH]; Unterer Rütshetenweg 38, CH-4133 Pratteln (CH).

(74) Agent: **LEON, Susanna, Iris**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYNTHESIS OF ACYLAMINOALKENYLENE AMIDES USEFUL AS SUBSTANCE P ANTAGONISTS




(57) Abstract: A process for preparing compounds of formula (I) or a solvate or hydrate thereof, where R, R¹, R², R³ and R⁵ have the meanings as indicated in the specification. Such compounds are useful in the treatment of a number of conditions associated with substance P and neurokinin.

WO 2007/118651 A1

SYNTHESIS OF ACYLAMINOALKENYLENE AMIDES USEFUL AS SUBSTANCE P ANTAGONISTS

This invention relates to the preparation of organic compounds, particularly an acylaminoalkylene amide derivative substance P antagonist.

More specifically, the present invention relates to a process for preparing compounds of formula I



or a solvate or hydrate thereof, where

R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R¹ is hydrogen or C₁-C₇-alkyl;


R² is hydrogen, C₁-C₇-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R³ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, or R³ is naphthyl, 1H-indol-3-yl or 1-C₁-C₇-alkyl-indol-3-yl; and

R⁵ is C₃-C₈-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Compounds of formula I are useful in the treatment of a number of conditions associated with substance P and neurokinin.

N-[(E)-(R)-1-(3,4-Dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide is a particularly preferred compound of formula I. It is also known as N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)-carbamoyl]-allyl-N-methyl-3,5-bis (trifluoromethyl)-benzamide and (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide and has the chemical structure of formula A




The compound of formula A, especially the hemihydrate thereof, is useful in the treatment of functional motility disorders of the viscera, such as irritable bowel syndrome or functional dyspepsia, especially diarrhoea-predominant irritable bowel syndrome.

Compounds of formula I can be prepared using the process described in international patent application WO 98/07694, the contents of which are incorporated herein by reference.

However the present invention relates to an improved process for preparing compounds of formula I and solvates and hydrates thereof, especially (4R)-4-[N'-methyl-N'-(3,5-bis(trifluoromethyl)-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, with high levels of safety, hygiene and ease of handling. It also facilitates the achievement of good yields on a production scale.

In a first aspect, the present invention provides a process for preparing compounds of formula I



or a solvate or hydrate thereof, where

R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R¹ is hydrogen or C₁-C₇-alkyl;


R² is hydrogen, C₁-C₇-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R³ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, or R³ is naphthyl, 1H-indol-3-yl or 1-C₁-C₇-alkyl-indol-3-yl; and


R⁵ is C₃-C₈-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl,

the process comprising the steps of:

- (a) reacting a compound of formula II




where R¹, R², R³ and R⁵ are as hereinbefore defined and T is a protecting group, with a base to form a compound of formula III



where R¹, R², R³ and R⁵ are as hereinbefore defined; and


- (b) reacting a compound of formula III where R¹, R², R³ and R⁵ are as hereinbefore defined with a compound of formula IV



where R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, and X is halo, in the presence of a base to form a compound of formula I, and

- (c) optionally, forming a desired solvate or hydrate thereof.

In a second aspect, the present invention provides a process for preparing compounds of formula I



or a solvate or hydrate thereof, where

R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R¹ is hydrogen or C₁-C₇-alkyl;


R² is hydrogen, C₁-C₇-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R³ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, or R³ is naphthyl, 1H-indol-3-yl or 1- C₁-C₇-alkyl-indol-3-yl; and

R⁵ is C₃-C₈-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl;


the process comprising the steps of:

- (i) reacting a compound of formula V




where R¹, R² and R³ are as hereinbefore defined and T is a protecting group with 2,2-dimethyl-[1,3]dioxane-4,6-dione in the presence of a base to form a compound of formula VI

5




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group;

- (ii) reacting the compound of formula VI where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group with methanol to give a compound of formula VII




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group;

- (iii) reducing the compound of formula VII where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group to form a compound of formula VIII




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group;

- (iv) hydrolysing the compound of formula VIII where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group to give the corresponding carboxylic acid of formula IX




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group;

- (v) reacting the compound of formula IX where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group with a compound of formula X




where R^5 is C_3 - C_8 -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl to form a compound of formula II




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group and R^5 is C_3 - C_8 -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl;

- (vi) optionally, purifying the compound of formula II where R^1 , R^2 , R^3 and R^5 are as hereinbefore defined and T is a protecting group;
- (vii) reacting the compound of formula II where R^1 , R^2 , R^3 and R^5 are as hereinbefore defined and T is a protecting group, with a base to form a compound of formula III



where R^1 , R^2 , R^3 and R^5 are as hereinbefore defined;

- (viii) reacting the compound of formula III where R^1 , R^2 , R^3 and R^5 are as hereinbefore defined is reacted with a compound of formula IV



where R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C_1 - C_7 -alkyl, trifluoromethyl, hydroxy and C_1 - C_7 -alkoxy, and X is halo, in the presence of a base to form a compound of formula I where R , R^1 , R^2 , R^3 and R^5 are as hereinbefore defined; and

- (ix) optionally, forming a desired solvate or hydrate thereof.

Terms used in the specification have the following meanings:

"Halogen" or "halo" as used herein denotes a element belonging to group 17 (formerly group VII) of the Periodic Table of Elements, which may be, for example, fluorine, chlorine, bromine or iodine. Preferably halogen or halo is chlorine or bromine, especially chlorine.

"C₁-C₇-alkyl" as used herein denotes a straight chain or branched alkyl group comprising 1 to 7 carbons, which may be, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, straight or branched pentyl, straight or branched hexyl or straight, or branched heptyl.

"C₁-C₇-alkoxy" as used herein denotes a straight chain or branched alkyl chain linked to O, which may be, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, straight or branched pentoxy, straight or branched hexyloxy, or straight or branched heptyloxy.

"C₃-C₈-cycloalkyl" as used herein denotes a fully saturated carbocyclic ring having 3 to 8 ring carbon atoms, for example a monocyclic group such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, or a bicyclic group such as bicycloheptyl or bicyclooctyl.

Throughout this specification and in the claims that follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

According to formula I, the following suitable, preferred, more preferred or most preferred aspects of the invention may be incorporated independently, collectively or in any combination.

R is suitably phenyl that is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy.

When R is phenyl substituted by C₁-C₇-alkyl it is suitably phenyl substituted by C₁-C₄-alkyl.

However when R is phenyl substituted by C₁-C₇-alkoxy it is suitably phenyl substituted by C₁-C₄-alkoxy.

R is more suitably phenyl that is substituted at one or two positions, especially two positions, by trifluoromethyl. R is especially 3,5-bis-trifluoromethyl-phenyl.

R¹ is suitably C₁-C₇-alkyl, more suitably C₁-C₄-alkyl, but especially suitably methyl.

R¹ is suitably hydrogen or C₁-C₇-alkyl.

R² is suitably hydrogen.

R³ is suitably phenyl that is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy.

R³ is more suitably phenyl that is substituted at one or two positions, especially two positions, by halo, especially chloro. R³ is especially suitably 3,4-dichloro-phenyl.

R⁵ is suitably D-azacycloheptan-2-on-3-yl.

Compounds of formula I or intermediate compounds that are used to prepare compounds of formula I can be pharmaceutically acceptable isotopically-labelled compounds of formula I or isotopically-labelled intermediate compounds that are used to prepare compounds of formula I respectively wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen e.g. ²H and ³H, carbon e.g. ¹¹C, ¹³C and ¹⁴C, chlorine e.g. ³⁶Cl, fluorine e.g. ¹⁸F, iodine e.g. ¹²³I and ¹²⁵I, nitrogen e.g. ¹³N and ¹⁵N, oxygen e.g. ¹⁵O, ¹⁷O and ¹⁸O, and sulfur e.g. ³⁵S.


Certain isotopically-labelled compounds of formula I, for example those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium (³H) and carbon-14 (¹⁴C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium (²H) may afford certain therapeutic advantages that result from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron

emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O , and ^{13}N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

Isotopically-labelling compounds of formula I or isotopically-labelling compounds of intermediate compounds that are used to prepare compounds of formula I can generally be achieved by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously used.

Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallisation may be isotopically substituted e.g. D_2O , d_6 -acetone or d_6 -DMSO.


Compounds of formula I can be prepared from a compound of formula V



where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group by carrying out the following multi step process.

In process steps 1 and 2, a compound of formula V as defined above is elongated by two carbon atoms.

In the first of these steps a compound of formula V where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group is reacted with 2,2-dimethyl-[1,3]dioxane-4,6-dione (meldrum's acid) in the presence of a base to form compounds of formula VI




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group or analogously e.g. as hereinafter described in the Examples.

This step is suitably carried out in the presence of base, for example dimethyl-pyridin-4-yl-amine. It is conveniently carried out in an organic solvent, for example toluene. The reaction temperature may be, for example, from room temperature to 60°C, preferably from 25°C to 35°C.

The protecting group T may be chosen from suitable protecting groups for the nature of the functional group, for example as described in *Protective Groups in Organic Synthesis*, T.W. Greene and P.G.M. Wuts, John Wiley & Sons Inc, Second Edition, 1991, which reference also describes procedures suitable for replacement of the protecting groups by hydrogen. The protecting group is suitably t-butoxycarbonyl or BOC.


In the process disclosed in WO 98/07694 for preparing compounds of formula I drug substance is obtained by separating two diastereoisomers of a late stage intermediate. This involves losing more than half of the material. Starting the present process with an optically active compound avoids this problem thus affording a significant improvement in yield and less waste.

In process step 2 the compound of formula VI where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group is reacted with methanol, preferably in the absence of water, to give a compound of formula VII



where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group or analogously e.g. as hereinafter described in the Examples.


In process step 3 the compound of formula VII where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group is reduced to give the corresponding (R)-hydroxy compound, i.e. a compound of formula VIII



where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group. The reaction is carried out using known procedures for reducing ketones or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in a mixture of organic solvents, for example tert-butyl methyl ether and methanol, and water. The reducing agent is suitably sodium borohydride. The reaction may be carried out at room temperature, but suitably from 15°C to 25°C.

The (R)-hydroxy compound obtained has the right configuration for the later formation of the trans double bond.

In process step 4 the compound of formula VIII where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group is hydrolysed to give the corresponding carboxylic acid i.e. a compound of formula IX




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group. The reaction is carried out using known procedures for hydrolysing esters to form carboxylic acids or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in a mixture of a water soluble organic solvent, for example tert-butyl methyl ether and methanol, and water. The hydrolysing agent is suitably a strong base such as lithium hydroxide monohydrate. The reaction may be carried out at room temperature, but preferably from 15°C to 25°C.

In process step 5 the compound of formula IX where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group is reacted with a compound of formula X



where R^5 is C₃-C₈-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl to form a compound of formula II

12




where R^1 , R^2 and R^3 are as hereinbefore defined and T is a protecting group and R^5 is C_3 - C_8 -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

The reaction is carried out using known procedures for reacting carboxylic acids with amines to form amide derivatives or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent, for example N-N-dimethylformamide. The reaction is suitably carried out at room temperature, but preferably from 15°C to 25°C.

In process step 6 the compound of formula II is purified, i.e. undesired isomers are removed. Surprisingly, this is achieved simply by stirring in an organic solvent, for example *t*-butyl methyl ether, at room temperature to 60°C, suitably 45°C to 55°C, but especially suitably about 50°C, to give a product of high purity.

In process step 7 the compound of formula II where R^1 , R^2 , R^3 and R^5 are as hereinbefore defined and T is a protecting group is reacted with a base to form a compound of formula III




where R^1 , R^2 , R^3 and R^5 are as hereinbefore defined. Normally, in beta-hydroxy esters or amides, the hydroxyl group first has to be transformed into a leaving group prior to base-induced elimination under formation of the trans double bond. However, surprisingly, in process 7 the trans double bond is introduced in a one-step base-induced simultaneous removal of both, the (R)-hydroxy and the BOC moiety. Furthermore, the corresponding isomer compound having the hydroxyl group in the (S) configuration, does *not* undergo this reaction.

The reaction is conveniently carried out in an organic solvent, for example tetrahydrofuran. The reaction temperature may be, for example, from -10°C to 10°C, suitably from -5°C to 5°C, but especially suitably from -2°C to 2°C. The reaction conditions given are optimised to keep

the formation of by-products on a low level: with bases stronger than for example sodium ethoxide in ethanol, more cis bond formation, shifting of the double bond to form the enamine and epimerisation in the caprolactam moiety are observed. With weaker bases, long reaction times and only partial conversion are achieved.

In process step 8 the compound of formula III where R¹, R², R³ and R⁵ are as hereinbefore defined is reacted with a compound of formula IV



where R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, and X is halo, suitably chloro, in the presence of a base to form a compound of formula I where R, R¹, R², R³ and R⁵ are as hereinbefore defined or a salt thereof.

The reaction is carried out using known procedures for reacting amines with acyl halides to form amide derivatives or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent, for example tert-butyl methyl ether, and the base is for example triethylamine. The reaction temperature may be, for example, from -10°C to 20°C, suitably from -5°C to 15°C, but especially suitably from 0°C to 5°C.

In process step 9, an optional step, the compound of formula I where R, R¹, R², R³ and R⁵ are as hereinbefore defined is crystallised in a suitable solvent to give the free compound, solvate or hydrate.


The compounds of formula I can be obtained in the form of the free compound, a hydrate or solvate thereof containing a solvent used for crystallization. For example when the compound of formula I is the compound of formula A it is crystallised from methanol and water to yield a stable drug substance hemihydrate.

The invention is illustrated by the following Example.


EXAMPLE

Preparation of N-[(E)-(R)-1-(3,4-Dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide hemihydrate

N-[(E)-(R)-1-(3,4-Dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide hemihydrate is prepared by the following process. All reactions are executed under a nitrogen atmosphere.



15



Steps 1 + 2: (R)-4-(tert-Butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-oxo-pentanoic acid methyl ester (4)

A solution of 1,3-dicyclohexylcarbodiimide (2.9011g, 13.9 mmol) in toluene (3 ml) is added to a stirred mixture of (R)-2-(tert-butoxycarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-propionic acid (1, 4.179g, 12 mmol), 2,2-dimethyl-[1,3]dioxane-4,6-dione (2, 1.7815 g, 12.36 mmol) and dimethyl-pyridin-4-yl-amine (2.0943g, 16.8 mmol) in toluene (32 ml) at 29-31°C over a period of approx. 1 hour. Toluene (1 ml) is used for rinsing. Stirring at 29-31°C is continued for approx. 3 hours. After cooling to ca. 0°C, a 25%w/w solution of potassium

hydrogen sulfate (approx. 9 ml) is added to the suspension at -2°C/2°C, until pH 2-3 is reached. Stirring is stopped and the layers are allowed to separate. The mixture is slowly stirred and filtrated cold (0-5°C) and the filter cake is rinsed with toluene (12 ml, 0-5°C). The layers of the filtrate are allowed to separate at approx. 0-5°C. The lower, aqueous layer is separated. The upper, organic layer, containing the intermediate [(R)-1-(3,4-dichloro-benzyl)-2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester (3) is passed through a filter charged with anhydrous sodium sulfate (5g) at 0-5°C and the filtrate is added to a reactor, containing methanol (18 ml, 20-25°C). The filter cake is rinsed with toluene (5 ml) and the filtrate is also added to the reactor. The resulting solution is heated (mantle temperature ca. 68°C) and stirred at approx. 63°C for approx. 4 hours, then concentrated at a mantle temperature of approx. 50°C under reduced pressure to obtain an oily residue, which is dissolved in tert-butyl methyl ether (24 ml) at normal pressure and a mantle temperature of ca. 50°C, then concentrated again under reduced pressure to obtain (R)-4-(tert-butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-oxo-pentanoic acid methyl ester (4) as an oily residue. The residue is dissolved again in tert butyl methyl ether (24 ml) at normal pressure and a mantle temperature of 50°C, then cooled to 18-22°C and used as such in the next step.

Step 3: (3R,4R)-4-(tert-Butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-hydroxy-pentanoic acid methyl ester (5)

Sodium borohydride (0.227g, 6 mmol) is added to the stirred solution of (R)-4-(tert-butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-oxo-pentanoic acid methyl ester (4) in tert-butyl methyl ether at 18-22°C. Water (3 ml) is added over a period of approx. 20 minutes at 18-22°C, then stirring is continued for approx. 15 minutes. Methanol (3 ml) is added over a period of approx. 30 minutes at 18-22°C, then stirring is continued for approx. 30 minutes to give a solution of (3R,4R)-4-(tert-butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-hydroxy-pentanoic acid methyl ester (5), which is used as such in the next step.

Step 4: (3R,4R)-4-(tert-Butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-hydroxy-pentanoic acid (6)

Water (3 ml) is added to the stirred reaction mixture containing (3R,4R)-4-(tert-butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-hydroxy-pentanoic acid methyl ester (5) at 18-22°C, then lithium hydroxide monohydrate (0.755g, 18 mmol) is added. Stirring at 18-22°C is continued for approx. 2 hours. Hydrochloric acid (approx. 12.6 ml of 2N, 25.2 mmol)) is added over a period of approx. 30 minutes, until pH 1.7-2.2 is obtained. Toluene

(12 ml) is added to the stirred mixture and stirring at 18-22°C is continued for approx. 10 minutes. Stirring is stopped and the layers are allowed to separate. The lower, aqueous layer is separated and the upper, organic layer is extracted with water (12 ml). Stirring is stopped and the lower, aqueous layer is separated. The organic layer is filtrated over a filter charged with anhydrous sodium sulfate (3g) in order to remove remains of water and 1,3-dicyclohexyl urea, the latter originating from step 1. The filter cake is rinsed with toluene (2 ml), then N,N-dimethylformamide (12 ml) is added to the filtrate. The resulting solution is concentrated by distilling toluene at a mantle temperature of approx. 50°C under reduced pressure, until the volume of the residue is approx. 14 ml. This resulting solution, containing (3R,4R)-4-(tert-butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-hydroxy-pentanoic acid (6) is used as such in the following step.

Step 5: [(1R,2R)-1-(3,4-Dichloro-benzyl)-2-hydroxy-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (8)

Triethylamine (1.396g = 1.91 ml, 13.8 mmol) is added to a stirred mixture of (R)-3-amino-azepan-2-one hydrochloride (7) in N,N-dimethylformamide (12 ml) at 18-22°C, then stirring is continued for approx. 1 hour. 1-Hydroxybenzotriazole hydrate (2.113g, 13.8 mmol) is added at 18-22°C to the stirred mixture, followed by the solution of (3R,4R)-4-tert-butoxycarbonyl-methyl-amino)-5-(3,4-dichloro-phenyl)-3-hydroxy-pentanoic acid (6) in N,N-dimethylformamide. N,N-dimethylformamide (2 ml) is used for rinsing. The mixture is cooled to 0-5°C, then 1,3-dicyclohexylcarbodiimide (2.847g, 13.8 mmol) is added, followed by N,N-dimethylformamide (1.5 ml), used for rinsing. Stirring at approx. 0-5°C is continued for approx. 1 hour, then the mixture is warmed to approx. 18-22°C and stirred at that temperature for approx. 20 hours. The precipitated solids are removed by filtration and the filter cake is rinsed with N,N-dimethylformamide (12 ml). The filtrate is concentrated at a mantle temperature of approx. 60°C under reduced pressure, until a concentrate of approx. 19.5g is obtained. The resulting suspension is cooled to approx. 20-25°C, then an aqueous solution of potassium hydrogencarbonate (1.92g, 19.17 mmol) in water (32 ml) is added over a period of approx. 20 minutes under evolution of carbon dioxide to give a suspension. The precipitated solids are isolated by filtration, rinsed with water (24 ml) and dried in vacuo at approx. 60°C to constant weight to yield crude [(1R,2R)-1-(3,4-dichloro-benzyl)-2-hydroxy-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (8) (6.019g, 99.8% of theory based on (R)-2-(tert-butoxycarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-propionic acid (1).

Step 6: [(1R,2R)-1-(3,4-Dichloro-benzyl)-2-hydroxy-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (9)

[(1R,2R)-1-(3,4-Dichloro-benzyl)-2-hydroxy-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (8) (6.019g) is added to stirred tert-butyl methyl ether (35 ml) at approx. 20-25°C. The mixture is heated to approx. 50-52°C and stirred at that temp. for about 1 hour. The suspension is cooled to approx. 0-5°C and stirred at that temperature for approx. 1 hour. The precipitated solids are isolated by filtration, rinsed with tert-butyl methyl ether (24 ml) and dried in vacuo at approx. 70°C to constant weight to yield [(1R,2R)-1-(3,4-dichloro-benzyl)-2-hydroxy-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (9) (4.2625g, 70.7% of theory based on (R)-2-(tert-butoxycarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-propionic acid (1). Purity: 98.5% area (hplc). The product is further purified by crystallization from dichloromethane/tert-butyl methyl ether: m.p. 186.8-187.4°C, MS-ES⁺: (MNa)⁺ = 524 (³⁵Cl₂), [α]_D²⁰ = + 17.24° (ethanol 94%).

Step 7: (E)-(R)-5-(3,4-Dichloro-phenyl)-4-methylamino-pent-2-enoic acid ((R)-2-oxo-azepan-3-yl)-amide (10)

A stirred mixture of [(1R,2R)-1-(3,4-dichloro-benzyl)-2-hydroxy-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (9) (1.005g, 2.0 mmol) and tetrahydrofuran (12 ml) is cooled to -2°C/2°C, then a 21% w solution of sodium ethoxide in ethanol (1.5 ml, 4.0 mmol) is added at -2°C/2°C over a period of approx. 20 minutes. The resulting solution is stirred at approx. 0°C for about 4.5 hours, then a 5%w aqueous solution of potassium hydrogencarbonate (0.253g, 2.53 mmol in 4.81g water) is added at approx. 0°C over a period of approx. 10 minutes. The temperature is raised to approx. 20°C, then toluene (17 ml) is added. After stirring the mixture for approx. 16 hours at ca. 20°C, stirring is stopped and the layers are allowed to separate. The lower, aqueous layer is separated and the organic layer is extracted with water (3.5 ml). The organic layer is concentrated at a mantle temp. of 60°C under reduced pressure, until approx. 10g of residue are obtained, causing the product to crystallise. After stirring at 60°C for approx. 10 minutes, distillation is continued, until a residue of about 5g is obtained. Water (0.36 ml) is added and stirring at 60°C is continued for approx. 30 minutes. The mixture is cooled to about 0°C over a period of ca. 30 minutes, then stirring at that temperature is continued for approx. 2 hours. The precipitated solids are isolated by filtration and the filter cake is rinsed with toluene (3 ml). After drying at approx. 60°C in vacuo to constant weight, (E)-(R)-5-(3,4-dichloro-phenyl)-4-methylamino-pent-2-enoic acid ((R)-2-oxo-azepan-3-yl)-amide (10) (0.580g, 75.5% of theory based on (9) is obtained: m.p. 153-158°C, MS-ES⁺: (MH)⁺ = 384 (³⁵Cl₂), [α]_D²⁰ = - 80.4° (ethanol).

Step 8: N-[(E)-(R)-1-(3,4-Dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide (12)


A stirred mixture of (E)-(R)-5-(3,4-dichloro-phenyl)-4-methylamino-pent-2-enoic acid ((R)-2-oxo-azepan-3-yl)-amide (10) (1.1529g, 3 mmol) in tert-butyl methyl ether (10 ml) is cooled to approx. 0°C. 3,5-bis-trifluoromethyl-benzoyl chloride (0.87g = 0.57 ml, 3.15 mmol) is added at 0-5°C over a period of approx. 15 minutes followed by triethylamine (0.319g = 0.44 ml, 3.15 mmol), which is added at approx. 0-5°C over a period of approx. 30 minutes. Stirring at 0-5°C is continued for approx. 10 minutes, then the mixture is warmed to 20-25°C over a period of approx. 30 minutes. The precipitated solids are removed by filtration and the filter cake is rinsed with tert-butyl methyl ether (5 ml). The filtrate is stirred and methanol (3 ml) is added. The solution is concentrated by distilling at a mantle temperature of approx. 50°C under reduced pressure, until a residue of approx. 10.5 ml is obtained. Methanol (8.5 ml) is added and the solution is concentrated again by distilling at a mantle temperature of approx. 50°C under reduced pressure, until a residue of approx. 10.5 ml is obtained. Again, methanol (8.5 ml) is added and the solution is concentrated by distilling at a mantle temperature of approx. 50°C under reduced pressure, until a residue of approx. 10.5 ml is obtained. The solution containing N-[(E)-(R)-1-(3,4-dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide (12) is cooled to 18-22°C and used as such in the next step.

Step 9: N-[(E)-(R)-1-(3,4-Dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide hemihydrate (13)

Water (2.6 ml) is added to the stirred solution (10.5 ml) of N-[(E)-(R)-1-(3,4-dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide (12) in methanol at approx. 18-22°C, whereupon crystallisation begins. After stirring for approx. 10 minutes, water (1 ml) is added at 18-22°C over a period of approx. 20 minutes. Stirring at 18-22°C is continued for 2 hours. The precipitated solids are isolated by filtration and the filter cake is rinsed with a mixture of methanol and water (2 ml + 1 ml), followed by water (3 ml). The solids are dried at 30°C in vacuo to constant weight to yield N-[(E)-(R)-1-(3,4-dichloro-benzyl)-3-((R)-2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide hemihydrate (13) [1.6241b = 85.5% of theory based on (E)-(R)-5-(3,4-dichloro-phenyl)-4-methylamino-pent-2-enoic acid ((R)-2-oxo-azepan-3-yl)-amide (10)], m.p. 127-131°C, sintering > 123°C, MS-ES⁺: (MH)⁺ = 624 (³⁵Cl₂), [α]_D²⁰ = + 40.6 ° (methanol).

CLAIMS

1. A process for preparing compounds of formula I



or a solvate or hydrate thereof, where

R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R¹ is hydrogen or C₁-C₇-alkyl;


R² is hydrogen, C₁-C₇-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy;

R³ is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, or R³ is naphthyl, 1H-indol-3-yl or 1- C₁-C₇-alkyl-indol-3-yl; and


R⁵ is C₃-C₈-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl,

the process comprising the steps of:

- (a) reacting a compound of formula II




where R¹, R², R³ and R⁵ are as defined in this claim above and T is a protecting group, with a base to form a compound of formula III



where R¹, R², R³ and R⁵ are defined in this claim above; and

- (b) reacting a compound of formula III where R^1 , R^2 , R^3 and R^5 are as defined in this claim above with a compound of formula IV




where R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C_1 - C_7 -alkyl, trifluoromethyl, hydroxy and C_1 - C_7 -alkoxy, and X is halo, in the presence of a base to form a compound of formula I, and

- (c) optionally, forming a desired solvate or hydrate thereof.


2. A process according to claim 1 wherein the reducing agent used in step (a) is sodium ethoxide.

3. A process according to claim 1 or claim 2 wherein the compound of formula II where R^1 , R^2 , R^3 , R^5 and T are as defined in claim 1 is prepared by the steps of:

- (i) reacting a compound of formula V




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group with 2,2-dimethyl-[1,3]dioxane-4,6-dione in the presence of a base to form a compound of formula VI




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group;

- (ii) reacting the compound of formula VI where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group with methanol to give a compound of formula VII




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group;

- (iii) reducing the compound of formula VII where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group to form a compound of formula VIII




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group;

- (iv) hydrolysing the compound of formula VIII where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group to give the corresponding carboxylic acid of formula IX



where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group; and

- (v) reacting the compound of formula IX where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group with a compound of formula X




where R^5 is C_3 - C_8 -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.


4. A process according to any preceding claim wherein the compound of formula I is (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide hemihydrate.

5. A process for preparing compounds of formula I as claimed in claim 1, the process comprising the steps of:

(i) reacting a compound of formula V




where R¹, R² and R³ are as defined in claim 1 and T is a protecting group with 2,2-dimethyl-[1,3]dioxane-4,6-dione in the presence of a base to form a compound of formula VI




where R¹, R² and R³ are as defined in claim 1 and T is a protecting group;

(ii) reacting the compound of formula VI where R¹, R² and R³ are as defined in claim 1 and T is a protecting group with methanol to give a compound of formula VII




where R¹, R² and R³ are as defined in claim 1 and T is a protecting group;

- (iii) reducing the compound of formula VII where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group to form a compound of formula VIII




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group;

- (iv) hydrolysing the compound of formula VIII where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group to give the corresponding carboxylic acid of formula IX




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group;

- (v) reacting the compound of formula IX where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group with a compound of formula X




where R^5 is C_3 - C_8 -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl to form a compound of formula II




where R^1 , R^2 and R^3 are as defined in claim 1 and T is a protecting group and R^5 is C_3 - C_8 -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl;

- (vi) optionally, purifying the compound of formula II where R^1 , R^2 , R^3 and R^5 are as defined in claim 1 and T is a protecting group;
- (vii) reacting the compound of formula II where R^1 , R^2 , R^3 and R^5 are as defined in claim 1 and T is a protecting group, with a base to form a compound of formula III



where R^1 , R^2 , R^3 and R^5 are as defined in claim 1;

- (viii) reacting the compound of formula III where R¹, R², R³ and R⁵ are as defined in claim 1 is reacted with a compound of formula IV



where R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₇-alkyl, trifluoromethyl, hydroxy and C₁-C₇-alkoxy, and X is halo, in the presence of a base to form a compound of formula I where R, R¹, R², R³ and R⁵ are as defined in claim 1; and

- (ix) optionally, forming a desired solvate or hydrate.

6. A process for preparing a compound of formula I as defined in claim 1 substantially as herein described with reference to any one of the Examples.

7. A process for preparing (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide hemihydrate substantially as herein described with reference to any one of the Examples.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/003213

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D223/12 A61K31/55 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98/07694 A (CIBA GEIGY AG [CH]; GERSPACHER MARC [CH]; VON SPRECHER ANDREAS [CH]; M) 26 February 1998 (1998-02-26) cited in the application claim 15 -----	1-7

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 August 2007

Date of mailing of the international search report

21/08/2007

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

MATES VALDIVIELSO, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/003213

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9807694	A	26-02-1998	
		AT 224875 T	15-10-2002
		AU 721850 B2	13-07-2000
		AU 4299397 A	06-03-1998
		BR 9711350 A	17-08-1999
		CA 2264065 A1	26-02-1998
		CN 1233238 A	27-10-1999
		CZ 9900581 A3	16-06-1999
		DE 69715886 D1	31-10-2002
		DE 69715886 T2	15-05-2003
		DK 923550 T3	06-01-2003
		EP 0923550 A1	23-06-1999
		ES 2184083 T3	01-04-2003
		HK 1021372 A1	20-06-2003
		HU 0001165 A2	28-11-2000
		ID 18059 A	26-02-1998
		IL 128631 A	12-09-2002
		JP 3654908 B2	02-06-2005
		JP 2001503387 T	13-03-2001
		NO 990786 A	25-03-1999
		NZ 334736 A	29-09-2000
		PL 331740 A1	02-08-1999
		PT 923550 T	31-01-2003
		RU 2185375 C2	20-07-2002
		SK 22199 A3	14-02-2000
		TR 9900363 T2	21-04-1999
		TW 438777 B	07-06-2001
		US 6319917 B1	20-11-2001
		ZA 9707493 A	03-08-1998